Trials / Completed
CompletedNCT01495533
Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter
Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated AngioSculpt Scoring Balloon - a First-in-man Pilot Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University Hospital, Saarland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the treatment of coronary Bare Metal Stent restenosis with a drug coated AngioSculpt scoring balloon.
Detailed description
Prospective, controlled, multicenter, randomized, single-blind trial. The aim is to examine the treatment of coronary Bare Metal Stent restenosis with a drug coated AngioSculpt scoring balloon. Patients are randomized to treatment by an AngioSculpt scoring balloon (no drug coating)or a drug coated AngioSculpt scoring balloon (paclitaxel 3.0 µg/mm²). Primary efficacy endpoint is late lumen loss in-segment at 6 months. Key secondary endpoints include procedural Success, MACE (cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization at 6 months). Individual clinical endpoints include stent thrombosis (ARC), cardiac death, any death, target vessel myocardial infarction, any infarction, clinically driven target lesion revascularization, clinically driven target vessel revascularization, any revascularization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | uncoated AngioSculpt(R) | Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating) |
| COMBINATION_PRODUCT | Drug coated AngioSculpt(R) | Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²) |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-12-01
- Completion
- 2014-07-01
- First posted
- 2011-12-20
- Last updated
- 2023-04-27
Locations
3 sites across 2 countries: Brazil, Germany
Source: ClinicalTrials.gov record NCT01495533. Inclusion in this directory is not an endorsement.